<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2571265&amp;fmt=gif">

The Rapid Blog

Resources

New Funding is Enabling Rapid Micro Biosystems to Expand the Global Use of Growth Direct™ at a Critical Time for Pharmaceutical and Vaccine Manufacturing

Posted by Rapid Micro Biosystems on May 20, 2020

Our recent press release outlines the ways in which $120 million in new funding will help us meet a growing demand for our automated microbial detection platform while continuing to support biopharmaceutical companies that must operate with reduced staff during the COVID-19 pandemic.


Watch this new video to see how simple it is to prevent human error in the QC lab using the Growth Direct system.

Growth Direct™ is the first, digitized platform for three critical QC applications: environmental monitoring, water testing, and bioburden testing. With Growth Direct, labs can eliminate 60% of the steps of manual methods and achieve:

  • Data integrity
  • Operational efficiencies
  • Higher quality products for improved patient outcomes
  • Compliance with the requirements of 21 CFR PART 11

From ensuring data integrity to making dropped cassettes a thing of the past, Growth Direct protects and tracks samples at every stage of testing.

1757RMB_TraditionalVsRapid_Graphic_0729_Final

Contact us for more information about how Growth Direct can help your lab reach greater production capacity and achieve reliable results.

Related articles: